MEZA ITP Study
Research type
Research Study
Full title
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia
IRAS ID
1010936
Contact name
Parth Patwari
Contact email
Sponsor organisation
Takeda Development Center Americas Inc.
Eudract number
2024-514401-54
Research summary
ITP is an autoimmune bleeding disorder that results in a decreased platelet count and may lead to bleeding events, some of which can be severe or life-threatening. Approximately 20% of patients with ITP do not respond to currently available treatments, or experience a loss of response or intolerance, resulting in increased bleeding-related morbidity and diminished quality of life. The purpose of this trial is to evaluate efficacy and safety of mezagitamab as a new treatment option that can provide a sustained platelet response, prevent bleeding, and improve the quality of life for patients with primary ITP who have had an insufficient response or intolerance to prior therapy.
REC name
London - Chelsea Research Ethics Committee
REC reference
25/LO/0035
Date of REC Opinion
31 Jan 2025
REC opinion
Further Information Favourable Opinion